A resorbable self-locking device (LigaTie) was developed to enable safe and easy surgical ligation of blood vessels. The aim of this study was to compare the long-term in vivo resorption of the device to a commercially available suture of equivalent material (Maxon) following ovarian pedicle ligation. After ovariohysterectomy follow-up ultrasound examinations were performed monthly on 21 dogs ligated with the device and 22 dogs ligated with the suture material until no hyperechoic remnants, acoustic shadowing or local tissue reactions were detected. In both groups, the ovarian pedicles gradually decreased in size. Ligation material was considered macroscopically resorbed when ultrasound showed no signs of the device or suture, ovarian pedicle or tissue reaction. Macroscopic resorption had occurred without signs of complications and was complete by four months for sutures and 5.5 months for the device. The results show that resorption time in vivo for the resorbable self-locking device is mildly longer than suture of the same material and that no complications of device resorption were detected, supporting that the resorbable self-locking device is safe for in vivo use.
- canine ovariohysterectomy
- absorbable implant
Statistics from Altmetric.com
Funding Grant to Resorbable Devices AB, Sweden, from VINNOVA (Sweden’s innovation agency).
Competing interests OVH is the inventor of the LigaTie device. Resorbable Devices, Sweden controls the patents describing the self-locking device and trademark LigaTie. Both OVH and NOB are part-owners of Resorbable Devices.
Ethics approval Approval to perform the study was obtained from the local ethical committee, reference UENF-CEUA 435813.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.